Live Analyst Rating Changes 23909 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Travis Steed
BofA

Travis Steed

Wall Street Analyst
★★★☆☆
#1070
on 13Foresight · ranked by our own returns
60%
Success Rate
+4.2%
Average Return
62 of 103 calls profitable · +0.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 60% of Travis Steed's ratings turned a profit when each position was held for 1 year — averaging +4.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

162 Buy 73 Hold 21 Sell
Travis's Stock Coverage 41 ratings · 2026-08-13
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
HAE
Haemonetics
Aug 12, 2026 BUY Buy
-15.0% avg upside
18 analysts
$100.00
15.31% Upside
+0.0% ·
MOBI
Mobia Medical, Inc.
Aug 11, 2026 BUY Strong Buy
+76.1% avg upside
4 analysts
$16.00
23.01% Upside
· ·
BBNX
Beta Bionics, Inc.
Aug 11, 2026 HOLD Strong Buy
+25.5% avg upside
14 analysts
$18.00
6.14% Upside
+4.3% ·
CBLL
Ceribell, Inc.
Aug 11, 2026 BUY Strong Buy
+10.6% avg upside
8 analysts
+0.0% ·
SOLV
Solventum Corporation
Aug 11, 2026 HOLD Buy
+7.5% avg upside
16 analysts
$95.00
13.86% Upside
+0.7% ·
GEHC
GE Healthcare Technologies Inc
Aug 11, 2026 HOLD Strong Buy
+13.5% avg upside
22 analysts
$74.00
2.87% Upside
+1.2% ·
ZBH
Zimmer Biomet Holdings
Aug 11, 2026 HOLD Buy
+17.5% avg upside
38 analysts
$110.00
15.23% Upside
+1.4% ·
SYK
Stryker
Aug 11, 2026 BUY Strong Buy
+6.5% avg upside
37 analysts
$380.00
11.17% Upside
· ·
ISRG
Intuitive Surgical
Aug 11, 2026 BUY Strong Buy
+19.8% avg upside
36 analysts
$470.00
17.73% Upside
-0.1% ·
BSX
Boston Scientific
Aug 11, 2026 BUY Strong Buy
+31.9% avg upside
38 analysts
$54.00
6.57% Upside
+0.4% ·
BDX
Becton Dickinson
Aug 11, 2026 HOLD Buy
+7.4% avg upside
25 analysts
$185.00
3.19% Upside
· ·
BAX
Baxter International
Aug 11, 2026 HOLD Buy
+23.2% avg upside
23 analysts
$28.00
4.54% Upside
· ·
ABT
Abbott Laboratories
Aug 11, 2026 BUY Strong Buy
+3.9% avg upside
36 analysts
$115.00
5.15% Upside
· ·
EMBC
Embecta Corporation
Aug 10, 2026 SELL Hold
+106.3% avg upside
5 analysts
-1.2% ·
MMED
MiniMed Group, Inc.
Aug 10, 2026 BUY Strong Buy
+8.6% avg upside
14 analysts
$24.00
22.16% Upside
· ·
TNDM
Tandem Diabetes Care
Aug 07, 2026 HOLD Buy
+40.3% avg upside
29 analysts
$25.00
8.66% Upside
+3.4% ·
GMED
Globus Medical
Aug 07, 2026 BUY Strong Buy
+8.4% avg upside
24 analysts
+3.4% ·
TFX
Teleflex
Aug 07, 2026 HOLD Buy
+38.9% avg upside
20 analysts
-1.1% ·
CARL
Carlsmed, Inc.
Aug 06, 2026 BUY Strong Buy
+37.0% avg upside
6 analysts
+0.1% ·
RXST
RxSight
Aug 05, 2026 SELL Hold
+26.8% avg upside
13 analysts
$6.50
6.78% Downside
-10.7% ·
SIBN
SI-Bone
Aug 04, 2026 BUY Strong Buy
+37.2% avg upside
18 analysts
+3.0% ·
INSP
Inspire Medical Systems
Aug 04, 2026 SELL Buy
+45.9% avg upside
21 analysts
$45.00
22.28% Downside
+9.1% ·
DXCM
Dexcom
Jul 31, 2026 BUY Strong Buy
+16.5% avg upside
32 analysts
+8.6% ·
MMSI
Merit Medical Systems
Jul 31, 2026 HOLD Strong Buy
+8.4% avg upside
15 analysts
+6.7% ·
BLCO
Bausch + Lomb Corporation
Jul 30, 2026 SELL Buy
+19.2% avg upside
19 analysts
+1.0% ·
CNMD
Conmed
Jul 30, 2026 SELL Hold
+30.9% avg upside
12 analysts
-4.6% ·
EW
Edwards Lifesciences
Jul 21, 2026 BUY Strong Buy
+8.1% avg upside
34 analysts
$100.00
8.39% Upside
+9.4% ·
KMTS
Kestra Medical Technologies Ltd.
Jul 16, 2026 BUY Strong Buy
+1.1% avg upside
9 analysts
$30.00
9.01% Upside
+15.9% ·
MDT
Medtronic
Jul 13, 2026 BUY Buy
+6.5% avg upside
38 analysts
$95.00
6.67% Upside
+7.1% ·
PODD
Insulet
Jun 23, 2026 BUY Strong Buy
+50.4% avg upside
32 analysts
$208.00
47.50% Upside
+0.2% ·
IART
Integra Lifesciences
May 14, 2026 SELL Buy
+149.7% avg upside
21 analysts
-17.9% ·
COO
Cooper Co
Mar 05, 2026 BUY Buy
+73.8% avg upside
21 analysts
$96.00
27.12% Upside
-4.3% ·
PEN
Penumbra
Jan 15, 2026 BUY Buy
+1.2% avg upside
23 analysts
-6.9% ·
PRCT
PROCEPT BioRobotics
Nov 05, 2025 BUY Buy
+46.2% avg upside
17 analysts
-30.8% ·
ITGR
Integer Holdings
Oct 24, 2025 HOLD Buy
-18.1% avg upside
16 analysts
$87.00
30.41% Downside
+71.5% ·
OM
Outset Medical
May 13, 2024 SELL Buy
+269.1% avg upside
8 analysts
$3.00
36.08% Downside
+62.9% ·
LUNG
Pulmonx
Sep 29, 2023 HOLD Buy
+218.6% avg upside
9 analysts
-19.8% ·
DXC
DXC Technology
Jan 06, 2021 SELL Hold
+154.5% avg upside
22 analysts
$24.00
127.53% Upside
-27.5% ·
LNTH
Lantheus
Sep 27, 2017 BUY Buy
-18.3% avg upside
21 analysts
$22.00
78.14% Downside
-17.1% ·
AXGN
AxoGen
Sep 25, 2017 BUY Strong Buy
-28.8% avg upside
21 analysts
$18.00
62.82% Downside
+98.4% ·
VRAYQ
Viewray
Aug 07, 2017 BUY Strong Buy
+558333233.3% avg upside
12 analysts
· ·
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Travis Steed — Frequently Asked Questions
How accurate are Travis Steed's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Travis's ratings were profitable over a one-year hold, with an average return of +4.1% per rating, or +0.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Travis ranked on 13Foresight?
Travis Steed is currently ranked #1070 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Travis cover?
Travis most recently has ratings on HAE, MOBI, BBNX, CBLL, SOLV, GEHC, ZBH, SYK, ISRG, BSX, BDX, BAX and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.